Inhalable powder formulation of a stabilized vasoactive intestinal peptide (VIP) derivative: Anti-inflammatory effect in experimental asthmatic rats

Peptides

Volumn 31, Issue 1, 2010, Pages 72-78

  Misaka, Shingen ^a   Aoki, Yosuke ^a   Karaki, Shin ichiro ^a   Kuwahara, Atsukazu ^a   Mizumoto, Takahiro ^b   Onoue, Satomi ^a   Yamada, Shizuo ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b ILS Inc   (Japan)

Author keywords

Asthma; Chronic obstructive pulmonary disease; Dry powder inhaler; Vasoactive intestinal peptide

Indexed keywords

EOSINOPHIL PEROXIDASE; IK 312532; LACTATE DEHYDROGENASE; MYELOPEROXIDASE; PEROXIDASE; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; CELL INFILTRATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE MARKER; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME RELEASE; EOSINOPHIL; GRANULOCYTE; HISTOPATHOLOGY; INFLAMMATORY CELL; LUNG ALVEOLUS EPITHELIUM; LUNG ALVEOLUS MACROPHAGE; MALE; NONHUMAN; PNEUMONIA; POWDER; PRIORITY JOURNAL; RAT;

ADMINISTRATION, INHALATION; ANIMALS; ANTI-INFLAMMATORY AGENTS; ASTHMA; BIOLOGICAL MARKERS; BRONCHOALVEOLAR LAVAGE FLUID; DISEASE MODELS, ANIMAL; L-LACTATE DEHYDROGENASE; MALE; PEROXIDASE; POWDERS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RATS; RATS, SPRAGUE-DAWLEY; VASOACTIVE INTESTINAL PEPTIDE;

ANIMALIA; RATTUS;

EID: 73049092065     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2009.09.032     Document Type: Article

References (36)

1. Abad C., Martinez C., Juarranz M.G., Arranz A., Leceta J., Delgado M., et al. Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease. Gastroenterology 124 (2003) 961-971
2. Barnes P.J. Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol 8 (2008) 183-192
3. Bhatia M., Saluja A.K., Hofbauer B., Frossard J.L., Lee H.S., Castagliuolo I., et al. Role of substance P and the neurokinin 1 receptor in acute pancreatitis and pancreatitis-associated lung injury. Proc Natl Acad Sci U S A 95 (1998) 4760-4765
4. Delgado M., Abad C., Martinez C., Leceta J., and Gomariz R.P. Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat Med 7 (2001) 563-568
5. Delgado M., Martinez C., Johnson M.C., Gomariz R.P., and Ganea D. Differential expression of vasoactive intestinal peptide receptors 1 and 2 (VIP-R1 and VIP-R2) mRNA in murine lymphocytes. J Neuroimmunol 68 (1996) 27-38
6. Drent M., Cobben N.A., Henderson R.F., Wouters E.F., and van Dieijen-Visser M. Usefulness of lactate dehydrogenase and its isoenzymes as indicators of lung damage or inflammation. Eur Respir J 9 (1996) 1736-1742
7. Endo K., Amikawa S., Matsumoto A., Sahashi N., and Onoue S. Erythritol-based dry powder of glucagon for pulmonary administration. Int J Pharm 290 (2005) 63-71
8. Frigas E., and Gleich G.J. The eosinophil and the pathophysiology of asthma. J Allergy Clin Immunol 77 (1986) 527-537
9. Glick Jr. J.H. Serum lactate dehydrogenase isoenzyme and total lactate dehydrogenase values in health and disease, and clinical evaluation of these tests by means of discriminant analysis. Am J Clin Pathol 52 (1969) 320-328
10. Goetzl E.J., Sreedharan S.P., Turck C.W., Bridenbaugh R., and Malfroy B. Preferential cleavage of amino- and carboxyl-terminal oligopeptides from vasoactive intestinal polypeptide by human recombinant enkephalinase (neutral endopeptidase EC 3. 4. 24. 11). Biochem Biophys Res Commun 158 (1989) 850-854
11. Gonzalez-Rey E., Chorny A., and Delgado M. Regulation of immune tolerance by anti-inflammatory neuropeptides. Nat Rev Immunol 7 (2007) 52-63
12. Groneberg D.A., Rabe K.F., and Fischer A. Novel concepts of neuropeptide-based drug therapy: vasoactive intestinal polypeptide and its receptors. Eur J Pharmacol 533 (2006) 182-194
13. Kallstrom B.L., and Waldeck B. Bronchodilating properties of the VIP receptor agonist Ro 25-1553 compared to those of formoterol on the guinea-pig isolated trachea. Eur J Pharmacol 430 (2001) 335-340
14. Kashimoto K., Nagano Y., Suitani Y., Hamanaka K., Mizumoto T., Tomizaki K., et al. Structure-activity relationship studies of PACAP-27 and VIP analogues. Ann N Y Acad Sci 805 (1996) 505-510
15. Martinez C., Abad C., Delgado M., Arranz A., Juarranz M.G., Rodriguez-Henche N., et al. Anti-inflammatory role in septic shock of pituitary adenylate cyclase-activating polypeptide receptor. Proc Natl Acad Sci U S A 99 (2002) 1053-1058
16. Misaka S., Sato H., Yamauchi Y., Onoue S., and Yamada S. Novel dry powder formulation of ovalbumin for development of COPD-like animal model: physicochemical characterization and biomarker profiling in rats. Eur J Pharm Sci 37 (2009) 469-476
17. Nicole P., Lins L., Rouyer-Fessard C., Drouot C., Fulcrand P., Thomas A., et al. Identification of key residues for interaction of vasoactive intestinal peptide with human VPAC1 and VPAC2 receptors and development of a highly selective VPAC1 receptor agonist. Alanine scanning and molecular modeling of the peptide. J Biol Chem 275 (2000) 24003-24012
18. Ohmori Y., Maruyama S., Kimura R., Onoue S., Matsumoto A., Endo K., et al. Pharmacological effects and lung-binding characteristics of a novel VIP analogue, [R15,20, 21, L17]-VIP-GRR (IK312532). Regul Pept 123 (2004) 201-207
19. Ohmori Y., Onoue S., Endo K., Matsumoto A., Uchida S., and Yamada S. Development of dry powder inhalation system of novel vasoactive intestinal peptide (VIP) analogue for pulmonary administration. Life Sci 79 (2006) 138-143
20. Onoue S., Endo K., Ohmori Y., Yamada S., Kimura R., Yajima T., et al. Long-acting analogue of vasoactive intestinal peptide, [R15, 20, 21, L17]-VIP-GRR (IK312532), protects rat alveolar L2 cells from the cytotoxicity of cigarette smoke. Regul Pept 123 (2004) 193-199
21. Onoue S., Hashimoto N., and Yamada S. Dry powder inhalation systems for pulmonary delivery of therapeutic peptides and proteins. Exp Opin Ther Patents 18 (2008) 1-13
22. Onoue S., Misaka S., Kawabata Y., and Yamada S. New treatments for chronic obstructive pulmonary disease and viable formulation/device options for inhalation therapy. Expert Opin Drug Deliv 6 (2009) 793-811
23. Onoue S., Misaka S., and Yamada S. Structure-activity relationship of vasoactive intestinal peptide (VIP): potent agonists and potential clinical applications. Naunyn Schmiedebergs Arch Pharmacol 377 (2008) 579-590
24. Onoue S., Ohmori Y., Endo K., Yamada S., Kimura R., and Yajima T. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide attenuate the cigarette smoke extract-induced apoptotic death of rat alveolar L2 cells. Eur J Biochem 271 (2004) 1757-1767
25. Onoue S., Yamada S., and Yajima T. Bioactive analogues and drug delivery systems of vasoactive intestinal peptide (VIP) for the treatment of asthma/COPD. Peptides 28 (2007) 1640-1650
26. Rawlings S.R., and Hezareh M. Pituitary adenylate cyclase-activating polypeptide (PACAP) and PACAP/vasoactive intestinal polypeptide receptors: actions on the anterior pituitary gland. Endocr Rev 17 (1996) 4-29
27. Said S.I. Vasoactive intestinal polypeptide (VIP) in asthma. Ann N Y Acad Sci 629 (1991) 305-318
28. Said S.I., and Mutt V. Polypeptide with broad biological activity: isolation from small intestine. Science 169 (1970) 1217-1218
29. Schneider T., van Velzen D., Moqbel R., and Issekutz A.C. Kinetics and quantitation of eosinophil and neutrophil recruitment to allergic lung inflammation in a brown Norway rat model. Am J Respir Cell Mol Biol 17 (1997) 702-712
30. Sergejeva S., Hoshino H., Yoshihara S., Kashimoto K., Lotvall J., and Linden A. A synthetic VIP peptide analogue inhibits neutrophil recruitment in rat airways in vivo. Regul Pept 117 (2004) 149-154
31. Shivers B.D., Gorcs T.J., Gottschall P.E., and Arimura A. Two high affinity binding sites for pituitary adenylate cyclase-activating polypeptide have different tissue distributions. Endocrinology 128 (1991) 3055-3065
32. Szema A.M., Hamidi S.A., Lyubsky S., Dickman K.G., Mathew S., Abdel-Razek T., et al. Mice lacking the VIP gene show airway hyperresponsiveness and airway inflammation, partially reversible by VIP. Am J Physiol Lung Cell Mol Physiol 291 (2006) L880-L886
33. Tsutsumi M., Claus T.H., Liang Y., Li Y., Yang L., Zhu J., et al. A potent and highly selective VPAC2 agonist enhances glucose-induced insulin release and glucose disposal: a potential therapy for type 2 diabetes. Diabetes 51 (2002) 1453-1460
34. Vaudry D., Gonzalez B.J., Basille M., Yon L., Fournier A., and Vaudry H. Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol Rev 52 (2000) 269-324
35. Werner-Klein M., Goggel R., Westhof A., and Erb K.J. Development and characterisation of a novel and rapid lung eosinophil influx model in the rat. Pulm Pharmacol Ther 21 (2008) 648-656
36. Winterbourn C.C., Vissers M.C., and Kettle A.J. Myeloperoxidase. Curr Opin Hematol 7 (2000) 53-58